Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Biol Chem. Author manuscript; available in PMC 2010 April 22.
Published in final edited form as:
PMCID: PMC2858560

Menin Induces Apoptosis in Murine Embryonic Fibroblasts


Multiple endocrine neoplasia type I (MEN1) is a hereditary tumor syndrome characterized by multiple endocrine and occasionally non-endocrine tumors. The tumor suppressor gene Men1, which is frequently mutated in MEN1 patients, encodes the nuclear protein menin. Although many tumor suppressor genes are involved in the regulation of apoptosis, it is unclear whether menin facilitates apoptosis. Here we show that ectopic overexpression of menin via adenoviruses induces apoptosis in murine embryonic fibroblasts (MEFs). The induction of apoptosis depends on Bax and Bak, two proapoptotic proteins. Moreover, loss of menin expression compromises apoptosis induced by UV irradiation and TNF-α, while complementation of menin-null cells with menin restores sensitivity to UV and TNF-α-induced apoptosis. Interestingly, loss of menin reduces the expression of procaspase 8, a critical protease that is essential for apoptosis induced by death-related receptors, whereas complementation of the menin-null cells upregulates the expression of procaspase 8. Furthermore, complementation of menin-null cells with menin increases the activation of caspase 8 in response to TNF-α treatment. These results suggest a proapoptotic function for menin that may be important in suppressing the development of MEN1.

Keywords: menin, MEN I, apoptosis, caspase 8, Bax/Bak, MEFs

Multiple endocrine neoplasia type I (MEN1) is a hereditary tumor syndrome which is characterized by tumors in multiple endocrine organs, including the pituitary, parathyroid glands, and the pancreatic islets (1,2). The spectrum of tumors found in MEN1 patients has recently been expanded to include other tumors such as lipomas, angiofibromas, melanomas, and collagenomas (1,3,4). The tumor suppressor gene mutated in MEN1 patients, Men1, was identified by positional cloning (5). Loss of heterozygosity at the Men1 locus is frequently observed in tumors from patients carrying a germline mutation in Men1 (1,2,6). Thus, mutations in Men1 lead to multiple tumors in endocrine as well as some non-endocrine tissues. Men1 encodes a nuclear protein of 610 amino acid residues (710), and its orthologs are found in mouse, rat, zebrafish, fruit fly, and snail (1014). Heterozygous Men1 knock-out mice develop a tumor syndrome that closely mimics human MEN1, indicating an essential role for menin in suppressing the development of the disease (15). However, menin does not display any known significant homology to any known consensus protein motifs. This makes it challenging to identify how menin functions as a tumor suppressor.

Menin interacts with a number of proteins, including the transcription factors JunD, NF-κB, Smad3, and Pem (1619). The interaction between menin and JunD or NF-κB inhibits their activation of gene transcription (16,17), presumably leading to inhibition of cell proliferation. Interaction of menin with Smad3, a signal transducer in the TGF-ß signaling pathway, may facilitate TGF-ß-induced inhibition of cell proliferation (18). Ectopic expression of menin in Ras-transformed NIH 3T3 cells inhibits cell proliferation (20). Although inhibition of cell proliferation may be one way in which menin suppresses tumorigenesis, many tumor suppressor genes, including p53 and BRCA1, regulate multiple cellular processes, including inhibition of growth, DNA repair, and apoptosis (21,22).

It is unclear whether menin plays a crucial role in apoptosis, although ectopic expression of menin in an insulinoma cell line increases the number of the cells stained by Annexin V, one marker for apoptosis (23). The current studies investigate the potential role of menin in promoting apoptosis, which could contribute to suppression of the development of MEN1. Here we demonstrate that overexpression of menin via adenoviruses results in apoptosis that depends on the presence of Bax and Bak, two proapoptotic proteins (24,25). Moreover, we show that targeted deletion of menin causes increased resistance to both UV and TNF-α-induced apoptosis. Furthermore, menin induces the expression of caspase 8, an essential component in death-related receptor pathways (26). In addition, cells complemented with menin display increased activation of caspase 8 in response to TNF-α treatment, consistent with their greater sensitivity to TNF-α mediated apoptosis. These results suggest that menin may suppress the development of MEN1, at least in part, by modulating apoptosis.


Plasmid Construction

PCR-amplified menin was inserted into the BglII and NotI site of the adenoviral shuttle vector (pAdTrack-CMV) (27) to generate pAdTrack-menin. Plasmids for generating recombinant retroviruses were made by inserting PCR-amplified human menin cDNA into the BamHI/NotI site of the retroviral vector pMX-puro. The constructs were sequenced to verify the fidelity of the sequence.

Production of Recombinant Adenoviruses and Retroviruses

Production of menin-expressing recombinant adenovirus is based on the pAdEasy system, a simplified method for generating recombinant adenovirus (27). Adenoviral titers were determined by plaque assay as well as fluorescence activated cell scanning (FACS) analysis for percentage of green fluorescent protein (GFP)-positive cells. Retroviruses were packaged using the Bosc23 packaging cell line as previously described (28).

Preparation of Immortalized Murine Embryonic Fibroblasts (MEFs)

Men1 ΔN3–8/+ mice (Men1+/) heterozygous for the Men1 locus were maintained on a 129s6/SvEvTac background (Taconic, Germantown, New York) (15). Men1+/ male and female mice were mated, and 9.5 days after plugging the females were euthanized. The embryos were placed in gelatin-coated 12-well plates and dissociated into single cells by repeated pipetting in trypsin buffer. LXSN16E6E7 retroviruses that express the human papillomaviral E6 and E7 open reading frame (29) were used to infect the primary MEFs to immortalize the cells. The infected MEFs were subjected to selection with 500 μg/ml G418. Two pairs of menin-null and menin-expressing MEF cell lines (heterozygous and wild-type), each pair derived from littermates, were established.

Establishment of Menin-Complemented MEF cell lines

Immortalized Men1−/− cells (< passage 12 after isolation from embryos) were seeded in 6-well plates on day 0, infected with vector or menin-expressing retroviruses on day 1, and switched to fresh medium on day 2. Cells were subjected to selection with 2 μg/ml puromycin on day 5 (72 h after switching to fresh medium).

Annexin V and Trypan Blue Staining

For Annexin V staining of adenovirus infected cells, 5 × 104 cells were seeded in a 6-well dish and allowed to attach for 5 hours. After attachment, cells were infected with adenoviruses (day 0). On the next day (day 1) the medium with adenoviruses was aspirated and fresh medium was added. On day 2 (24 hours after switching to fresh medium), cells were processed for staining. Briefly, cells were collected, stained with Annexin V-Cy5 as instructed by the manufacturer (MBL International Inc, Watertown, MA), and analyzed on a Becton-Dickinson LSR cytometer (San Jose, CA). The percentage of Annexin-V positive cells was determined from gated GFP-positive cell populations.

To examine apoptosis of the menin-null MEFs infected with either vector retroviruses or retroviruses expressing menin, the cells were passaged for approximately 2 weeks after initial retroviral infection in order to obtain sufficient numbers of cells for experiments. For trypan blue staining to detect loss of membrane integrity, 8×104 cells were seeded in a 60 mm dish on day 0. On day 1, cells were treated with or without UV irradiation (100 mJ/m2) by a Spectrolinker XL-1000 (Spectronics Corporation, Westbury, NY), or with or without without TNF-α (10 ng/mL, R&D Systems, Minneapolis, MN)/cycloheximide (5.0 μg/mL, Sigma, St. Louis, MO). On day 2 (24 hours after the treatment), the cells were collected, stained with trypan blue (0.2%), and counted. Duplicate samples were examined for each data point.

To provide an independent assessment of apoptosis in response to UV or TNF-α treatment, Annexin V staining was measured at 16 h after respective treatments. Briefly, 3×105 cells were seeded per 100 mm dish on day 0, treated or not treated on day 1, and harvested 16 h after the treatment on day 2. Cells were collected and stained with Annexin V-FITC from the MEBCYTO® Apoptosis Kit as instructed by the manufacturer (MBL International Inc., Watertown, MA).

Detection of Release of Free Nucleosomal DNA

Cells were harvested 24–30 h after infection with adenoviruses. The cells were pelleted by centrifugation and their densities were adjusted to 105/ml using the cell lysis buffer from the Cell Death Detection kit (Roche, Indianapolis, IN). The cell lysate was diluted 10 fold and 100 μl was used to detect the release of free nucleosomal DNA by ELISA, based on instructions from the manufacturer.

Western Blotting Analysis

To detect menin expression, whole cell lysates were prepared with whole cell lysis buffer (50mM Hepes, pH 7.5, 0.4% Triton-X-100, 0.1% NP-40, 150mM NaCl, 10mM MgCl2, 0.5mM EDTA, 2.5mM EGTA, 0.2mM Na3VO4, 1mM NaF, 10mM β-glycerophosphate, 1mM DTT, 0.2mM PMSF, 4 μg/ml of Leupeptin, Aprotenin, and Pepstatin A). Nuclear extracts were prepared as previously described (28). The primary antibody against a human menin peptide (S593–L610) (30) was raised in rabbits and was affinity purified with the corresponding peptide conjugated agarose beads. The bound primary antibodies were detected as previously described (31). To detect procaspase 8 expression, whole cell lysates were prepared from freshly isolated cells using CHAPS lysis buffer (10 mM Tris, pH 7.5, 0.5% CHAPS, 1 mM MgCl2, 1 mM EGTA, 10% glycerol, 1 mM sodium-o-vanadate, and 0.1 mg/mL Pefabloc) supplemented with a protease inhibitor cocktail (CalBiochem, La Jolla, CA), as previously described (32). Western blotting was performed using a monoclonal antibody from Alexis (ALX-804-448; San Diego, CA).

DNA Microarray and Northern Blotting Analysis

For the microarray, the vector or menin-complemented MEFs were seeded at a density of 2.5 × 105 cells/100 mm dish on day 0. The cells were harvested on day 2 for isolation of RNA using the cesium chloride centrifugation method (33). To increase the reproducibility of gene expression profiles, two independent preparations of RNA from each of the cell lines were analyzed. The RNA was processed to generate biotin-labeled RNA probes (34). The probes were hybridized to the Affymetrix Murine GeneChip U74A array at The Penn Microarray Core Facility. Genes whose levels of expression varied twofold or more from the control were further analyzed by Northern blotting analysis, which was carried out as previously described (31).

Caspase 8 Enzyme Activity Assay

To compare caspase 8 enzyme activities in vector-complemented and menin-complemented MEFs treated with TNF-α, 3×105 cells were seeded in 100 mm dishes on day 0. Starting on day 1, TNF-α (10 ng/mL)/cycloheximide (5 μg/mL) was added 0, 3, 6, 12, and 24 h prior to harvesting cells for analysis. Cells were harvested using CHAPS lysis buffer, and protein concentration was determined using BCA reagents (Pierce, Rockford, IL). The reaction mixtures consisted of the following components: 80 μL caspase 8 assay buffer (0.1 M Tris-Cl, pH 8.0, 1 mM EDTA, 1 mM sucrose, 10 % glycerol, supplemented with 10 mM DTT), 100 μg whole cell lysates, 0.5 μL Ac-IETD-FAC (Pharmingen, San Diego, CA), a highly specific caspase 8 substrate, in a final volume of 160 μL. The mixture was incubated for 2 h at 37 °C and measured on a fluorometer with an excitation wavelength of 400 nm and an emission wavelength of 480–520 nm (BioRad, Hercules, CA). The result from 0 h of TNF-α treament was set to zero and used to normalize the other measurements. All time points were performed in triplicate.

Statistical Analysis and Quantitation

Standard error bars are noted for appropriate experiments, using Microsoft Excel. Quantitation was performed using either NIH Image 1.63 Software (NIH, Bethesda, MD) or Imagequant software (Amersham Biosciences, Piscataway, NJ).


Adenovirus-mediated Expression of Menin in MEFs Results in Apoptosis

To examine the biological effects of overexpression of menin, we generated menin-expressing adenoviruses (Ad-menin) and control adenoviruses (Ad-GFP). Ad-menin and Ad-GFP, each of which expresses green fluorescent protein (GFP), were used to infect immortalized murine embryonic fibroblasts (MEFs). Figure 1A shows that Ad-menin, but not Ad-GFP, causes the majority of infected cells to shrink and detach from the bottom of the plate, characteristic of apoptotic cells. The infection efficiency of Ad-menin and Ad-GFP was similar (Fig. 1A, Bottom panels). These results suggest that overexpression of menin results in death of the MEFs.

FIG. 1
Overexpression of menin from recombinant adenoviruses leads to apoptosis in MEFs

To examine whether Ad-menin induces apoptosis, the cells were infected with increasing multiplicities of infection (MOIs, from 0 to 20) of either Ad-menin or control Ad-GFP. The infected cells were stained with fluorescent-labeled Annexin V, which specifically binds to phosphatidylserine residues that flip from the inner leaflet to the outer leaflet of the plasma membrane during apoptosis (35). The Annexin V-stained cells were detected by fluorescence activated cell scanning (FACS). Figure 1B shows that infection of the cells with Ad-menin increases the percentage of the Annexin V-stained cells from 7% to 58% (with MOIs from 0 to 20). In contrast, infection of the cells with Ad-GFP only slightly increases this percentage (from 10% to 18%). These results suggest that ectopic expression of menin results in apoptosis in a dose-dependent manner.

Analysis of another marker of apoptosis, release of free nucleosomal DNA (36), confirms the above finding (Fig. 2A). The cells were infected with two independent clones of Ad-menin or Ad-GFP before analyzing the release of free nucleosomal DNA. Figure 2A shows that Ad-GFP results in only a low level of release of free nucleosomal DNA (0.2 –0.3 units), but Ad-menin leads to a marked enhancement of the release of free nucleosomal DNA (0.7–0.9 units). The expression of menin from Ad-menin in the cells was confirmed by immunoblotting using an anti-menin antibody (Fig. 2B). Collectively, these results indicate that overexpression of menin, but not GFP, leads to apoptosis in the infected cells. This is consistent with a recent report showing an increased number of Annexin V-stained cells in an insulinoma cell line stably overexpressing menin (23).

FIG. 2
Ad-menin increases the release of free nucleosomal DNA

Ad-menin induces Apoptosis through a Bax/Bak-dependent Apoptotic Pathway

To identify the apoptotic pathway that menin activates and to rule out that overexpression of menin simply results in a non-specific toxicity, we examined whether ablation of Bax and Bak, two proapoptotic genes essential for multiple apoptotic pathways (37), blocks Ad-menin-mediated apoptosis. Immortalized wild-type and Bax−/−/Bak−/− double knock out (DKO) MEFs (24) were infected with increasing MOIs of Ad-menin or Ad-GFP. In contrast to the shrinkage and detachment we observed in normal cells (Fig. 1A), we saw no such changes in the DKO MEFs (data not shown). To confirm the lack of apoptosis in the DKO cells, the infected cells were stained with Annexin V. Analysis by flow cytometry shows that the background Annexin V-staining accounts for 2–4% of the control wild type and DKO cells (Fig. 3A). Infection of the wild type cells with increasing MOIs of Ad-menin markedly increases the percentage of the apoptotic cells (54%), while Ad-GFP only slightly increases this percentage (14%, Fig. 3A). In contrast, even at the highest MOI, Ad-menin and Ad-GFP cause similar amounts of apoptosis in DKO cells (13 %, Fig. 3A).

FIG. 3
Ad-menin induces apoptosis through a Bax/Bak-dependent pathway

In agreement with the above results, infection of wild type cells with increasing MOIs of Ad-GFP only slightly increases the release of free nucleosomal DNA, from 0.3 units to 0.5 units (Fig. 3B, columns 1–4). In contrast, Ad-menin increases the release of free nucleosomal DNA in the wild type cells from 0.3 to 1.1 units (columns 1 and 5–7), indicating a role for menin in inducing apoptosis. Infection of the DKO cells with Ad-GFP does not increase the release of free nucleosomal DNA (Fig. 3B, columns 8–11). In contrast to the wild type cells, DKO cells infected with Ad-menin do not show cleavage of nucleosomal DNA (Fig. 3B, columns 8 and 12–14), although both the wild type and DKO cells express a similar level of menin after infection (Fig. 3C). Collectively, these results indicate that menin-mediated apoptosis is dependent on Bax and Bak (25) and that the Ad-menin-induced cell death is not a non-specific cytotoxicity induced by overexpression of menin.

Complementation of Menin-null MEFs with Menin Sensitizes the Cells to UV and TNF-α-induced Apoptosis

Next, we determined whether loss of menin expression, which is similar to what occurs in tumors, affects cellular response to apoptosis. We introduced menin into the immortalized menin-null MEFs by retroviral infection, generating stable cell lines. Figure 4A shows that menin is expressed in the menin-complemented cells but not in vector-complemented cells. The cells were then treated with UV irradiation, a well-known apoptotic signal, and stained with either trypan blue to detect disruption of cell membrane integrity or Annexin V to detect phosphatidylserine translocation. Figure 4B shows that only 11 % of the menin-null cells die after UV treatment, whereas 31 % of the menin-complemented cells undergo apoptosis under the same conditions. Levels of apoptosis in untreated cells are similar. Consistent with this, only 11 % of the vector-complemented cells are stained positive for Annexin V after UV irradiation, while 26 % of the UV-treated menin-complemented cells are Annexin-V positive (Fig. 4C). These results suggest that introduction of menin back into the menin-null cells renders the cells more sensitive to UV-induced apoptosis.

FIG. 4
Complementation of the menin-null MEFs with menin enhances their sensitivity to UV and TNF-α induced apoptosis

To test whether menin might also be critical for maximal response to other apoptotic signals, we examined whether loss of menin affects the cellular response to TNF-α, which induces apoptosis by binding to death receptors (38). Vector-complemented cells and menin-complemented cells were treated with TNF-α and stained with either trypan blue or Annexin V. Figure 4D shows that only 17 % of the vector-complemented cells die after TNF-α treatment, compared to 49 % of the menin-complemented cells. Staining for Annexin V further confirms these results, as 16 % of the vector-complemented cells undergo TNF-α-mediated apoptosis versus 61 % of the menin-complemented cells (Fig. 4E). These results indicate that introduction of menin into menin-null MEFs sensitizes the cells to TNF-α-induced apoptosis.

Menin Induces the Expression of Procaspase 8 mRNA

Since menin is primarily a nuclear protein and is implicated in control of transcription (39,40), we performed DNA microarray analysis on vector-complemented cells and menin-complemented cells to determine whether any menin-regulated genes are involved in apoptosis. Procaspase 8, a critical protease that is activated by various death receptors that bind TNF-α or Fas ligand (26,38), was identified as a gene that is upregulated by menin. Procaspase 8 is essential for apoptosis induced by these death receptors. Upon binding of apoptotic ligands such as TNF-α, the activated death receptors recruit adaptor proteins such as FADD, which in turn binds procaspase 8, leading to generation of active caspase 8 by proteolytic cleavage (26,38). In addition, several members of the homeobox (HOX) gene family as well as the insulin growth factor binding protein (IGFBP) family were also found to be differentially regulated by menin in the DNA microarray analysis. However, it is not yet clear whether these members are involved in menin-related apoptosis.

Given the clear role of procaspase 8 in apoptosis, we chose to focus our studies on its regulation by menin. Two pairs of immortalized menin-null cell lines and menin-expressing cell lines, each from a distinct group of littermates, were established from E9.5 day embryos (Fig. 5A). Expression of menin from these cells was detected as expected, based on genotyping (data not shown) and Western blotting analysis (Fig. 5A). Expression of procaspase 8 mRNA is 2.9 fold higher in menin-expressing cells than in menin-null cells from the first group of littermates, while expression of procaspase 8 is 1.6 fold higher in menin-expressing cells in the second group of littermates (Fig. 5B, top panel).

FIG. 5
Menin positively regulates the expression of the procaspase 8 mRNA

To further confirm that menin is responsible for upregulation of procaspase 8, one of the menin-null cell lines was infected with control retroviruses or viruses expressing menin, and the expression of transduced menin in the infected cells was confirmed by Western blotting analysis (Fig. 6A). Figure 6B indicates that complementation of the menin-null cells with menin enhances the level of the procaspase 8 mRNA 3.0 fold. Thus, these results indicate that targeted deletion of menin results in decreased levels of the procaspase 8 mRNA (Fig. 5B) whereas restoration of menin increases the levels of the procaspase 8 mRNA (Fig. 6B).

FIG. 6
Complementation of menin-null MEFs with menin increases the expression of procaspase 8 mRNA

Menin Induces the Expression of Procaspase 8 Protein as well as Caspase 8 Enzymatic Activity in TNF-α treated cells

To examine whether menin-mediated upregulation of the procaspase 8 mRNA leads to increased expression of procaspase 8, three independent pairs of control cell lines and menin-complemented cell lines were generated. The levels of the procaspase 8 protein from the three pairs were detected by Western blotting analysis. Figure 7A indicates that complementation with menin enhances expression of the procaspase 8 protein in all three pairs of cell lines. The enhanced levels range from 2.1 to 2.5 fold. In addition, enhanced levels of procaspase 8 may lead to increased caspase 8 activity in response to TNF-α. As shown in Figure 7B, caspase 8 activity indeed significantly increases in response to the treatment with TNF-α (p<.004 24 h after treatment with TNF-α), in a time-dependent manner, in menin-complemented cells, while its activity only slightly increases in the control vector-infected cells. Collectively, these results suggest that menin enhances apoptosis at least in part by upregulation of procaspase 8 protein and, accordingly, the caspase 8 activity after activation of the death receptors.

FIG. 7
Complementation of menin-null MEFs with menin increases the expression of procaspase 8 protein as well as the TNF-α-activated caspase 8 activity


Menin, a potent tumor suppressor which suppresses the development of MEN1, interacts with various transcription factors and inhibits the proliferation of oncogenic Ras-transformed cells (20,39). While the role of menin in the regulation of cell proliferation has been studied, its role in apoptosis has remained unexplored. The current studies suggest a potentially critical role for menin in promoting apoptosis. Transient overexpression of menin in MEFs induces apoptosis that is dependent on the presence of Bax and Bak, two crucial proapoptotic proteins (Figs. 13). Complementation of menin-null MEFs with menin, but not vector, renders the cells more sensitive to both UV and TNF-α induced apoptosis (Fig. 4). These findings indicate that extremely high levels of menin induced by recombinant adenoviruses (10 times higher than that mediated by retroviral infection; data not shown) can directly cause apoptosis. In contrast, the more physiologically relevant levels of menin induced by retroviruses modulate apoptosis in the presence of apoptotic signals, namely UV and TNF-α. Perhaps transient, extremely high levels of menin resulting from adenovirus infection trigger downstream apoptotic pathways even in the absence of apoptotic stimuli, whereas physiologically relevant levels of menin potentiate apoptosis induced by various apoptotic signals. Similarly, adenovirus-mediated expression of the tumor suppressor PTEN directly results in increased apoptosis in certain cancer cells, whereas endogenous levels of PTEN do not trigger apoptosis (4244).

In addition to promoting increased resistance to apoptotic stimuli, loss of the Men1 gene leads to decreased expression of procaspase 8 mRNA, a critical protease in death-receptor-mediated apoptosis (Fig. 5). Moreover, complementation of menin-null MEFs with menin leads to increased caspase 8 mRNA and protein expression (Figs. 6 and and7).7). Complementation with menin also leads to increased caspase 8 activation in cells treated with TNF-α, correlating with increased sensitivity to TNF-α. Given the interaction of menin with other transcription factors including JunD, NF-κB, Smad3 and Pem, menin may directly act as a transcriptional co-regulator to modulate the expression of procaspase 8. Alternatively, it may be involved in modifying the promoter of procaspase 8 or the chromatin structure surrounding the promoter. For instance, the promoter of human procaspase 8 has been shown to be methylated in neuroblastoma cells, leading to its decreased expression (45,46). It is also possible that menin may affect other proteins to indirectly regulate expression of procaspase 8.

The ability of menin to upregulate caspase 8 expression and its enzymatic activity could help to explain the pro-apoptotic role of menin in cells treated with TNF-α. TNF-α triggers apoptosis by binding to the TNF-α receptor, which subsequently recruits adapter proteins that lead to the activation of caspase 8 and the initiation of the apoptotic cascade (38). Menin may therefore potentiate the TNF-α mediated apoptotic signal by increasing the amount of procaspase 8 and its activity. However, it is likely that the modulation of caspase 8 is not the only way in which menin promotes apoptosis. Menin may also modulate the expression of other pro-apoptotic or anti-apoptotic genes to regulate apoptosis. Nevertheless, in the DNA microarray analysis, no other genes related to the caspase 8 pathway were differentially regulated by menin.

In conclusion, these studies indicate a role for menin in promoting apoptosis and the expression of procaspase 8. They suggest apoptosis as another critical function of menin, in addition to inhibition of cell proliferation (20,23,47,48) and involvement in DNA repair (30,47,4951). Attenuation of normal apoptosis in endocrine cells, in combination with increased proliferation and compromised DNA repair capabilities in menin-null cells, may allow cells to accumulate oncogenic mutations, facilitating the development of tumors. Collectively, the current studies suggest a critical role for menin in apoptosis and shed light on the pathogenesis of MEN I.


This work is in part supported by a Howard Temin Award (K01CA78592 to XH), a Burroughs Wellcome Career Award (#1676 to XH), an award from the Rita Alan Foundation (to XH), and an American Cancer Society grant (RSG-03-055-01-LIB). We thank Dr. Sunit Agarwal at NIH/NIDDK for the pCMV-Sport-menin construct, Drs. Judy Crabtree and Francis Collins at NHGRI for Men1+/ mice, Dr. Richard Carroll for LXSN16E6E7 retroviruses, and Dr. J. Alan Diehl for p19Arf−/− MEFs. We are grateful to Dr. Aimee Edinger for assistance with FACS analysis, Drs. Brian Keith and Celeste Simon for advice on MEF preparation, Drs. C. Thompson and T. Linsden for Bax−/−/Bak−/− DKO cells, and Drs. Xiaolu Yang, David Chang, Hongtu Liu, and Leonardo Salmena for helpful discussions. We thank Dr. Don Baldwin of the Penn Microarray Facility for technical advice and discussions. We thank Drs. Gary Koretzky, Craig Thompson, Michael Brown, and Joseph Goldstein for critically reading the manuscript. We thank Mark Kessler for help in preparing the manuscript.


1. Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, James LA, Goldsmith PK, Saggar SK, Park SY, Spiegel AM, Burns AL, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Emmert-Buck MR, Guru SC, Manickam P, Crabtree J, Erdos MR, Collins FS, Chandrasekharappa SC. Recent Prog Horm Res. 1999;54:397–438. [PubMed]
2. Pannett AA, Thakker RV. Endocr Relat Cancer. 1999;6:449–473. [PubMed]
3. Nord B, Platz A, Smoczynski K, Kytola S, Robertson G, Calender A, Murat A, Weintraub D, Burgess J, Edwards M, Skogseid B, Owen D, Lassam N, Hogg D, Larsson C, Teh BT. Int J Cancer. 2000;87:463–467. [PubMed]
4. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, Marx SJ. Trends Endocrinol Metab. 2001;12:173–178. [PubMed]
5. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, Crabtree JS, Wang Y, Roe BA, Weisemann J, Boguski MS, Agarwal SK, Kester MB, Kim YS, Heppner C, Dong Q, Spiegel AM, Burns AL, Marx SJ. Science. 1997;276:404–407. [PubMed]
6. Thakker RV. Endocrinol Metab Clin North Am. 2000;29:541–567. [PubMed]
7. Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, Chandrasekharappa SC. Proc Natl Acad Sci U S A. 1998;95:1630–1634. [PubMed]
8. Kaji H, Canaff L, Goltzman D, Hendy GN. Cancer Res. 1999;59:5097–5101. [PubMed]
9. Wautot V, Khodaei S, Frappart L, Buisson N, Baro E, Lenoir GM, Calender A, Zhang CX, Weber G. Int J Cancer. 2000;85:877–881. [PubMed]
10. Stewart C, Parente F, Piehl F, Farnebo F, Quincey D, Silins G, Bergman L, Carle GF, Lemmens I, Grimmond S, Xian CZ, Khodei S, Teh BT, Lagercrantz J, Siggers P, Calender A, Van de Vem V, Kas K, Weber G, Hayward N, Gaudray P, Larsson C. Oncogene. 1998;17:2485–2493. [PubMed]
11. Guru SC, Prasad NB, Shin EJ, Hemavathy K, Lu J, Ip YT, Agarwal SK, Marx SJ, Spiegel AM, Collins FS, Oliver B, Chandrasekharappa SC. Gene. 2001;263:31–38. [PubMed]
12. Khodaei S, O’Brien KP, Dumanski J, Wong FK, Weber G. Biochem Biophys Res Commun. 1999;264:404–408. [PubMed]
13. Manickam P, Vogel AM, Agarwal SK, Oda T, Spiegel AM, Marx SJ, Collins FS, Weinstein BM, Chandrasekharappa SC. Mamm Genome. 2000;11:448–454. [PubMed]
14. van Kesteren RE, Syed NI, Munno DW, Bouwman J, Feng ZP, Geraerts WP, Smit AB. J Neurosci. 2001;21:RC161. [PubMed]
15. Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC, Marx SJ, Spiegel AM, Collins FS. Proc Natl Acad Sci U S A. 2001;98:1118–1123. [PubMed]
16. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL. Cell. 1999;96:143–152. [PubMed]
17. Heppner C, Bilimoria KY, Agarwal SK, Kester M, Whitty LJ, Guru SC, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL. Oncogene. 2001;20:4917–4925. [PubMed]
18. Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN. Proc Natl Acad Sci U S A. 2001;98:3837–3842. [PubMed]
19. Lemmens IH, Forsberg L, Pannett AA, Meyen E, Piehl F, Turner JJ, Van de Ven WJ, Thakker RV, Larsson C, Kas K. Biochem Biophys Res Commun. 2001;286:426–431. [PubMed]
20. Kim YS, Burns AL, Goldsmith PK, Heppner C, Park SY, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ. Oncogene. 1999;18:5936–5942. [PubMed]
21. Levine AJ. Cell. 1997;88:323–331. [PubMed]
22. Scully R, Livingston DM. Nature. 2000;408:429–432. [PMC free article] [PubMed]
23. Sayo Y, Murao K, Imachi H, Cao WM, Sato M, Dobashi H, Wong NC, Ishida T. Endocrinology. 2002;143:2437–2440. [PubMed]
24. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, Frauwirth K, Chen Y, Wei M, Eng VM, Adelman DM, Simon MC, Ma A, Golden JA, Evan G, Korsmeyer SJ, MacGregor GR, Thompson CB. Mol Cell. 2000;6:1389–1399. [PMC free article] [PubMed]
25. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Science. 2001;292:727–730. [PMC free article] [PubMed]
26. Varfolomeev EE, Schuchmann M, Luria V, Chiannilkulchai N, Beckmann JS, Mett IL, Rebrikov D, Brodianski VM, Kemper OC, Kollet O, Lapidot T, Soffer D, Sobe T, Avraham KB, Goncharov T, Holtmann H, Lonai P, Wallach D. Immunity. 1998;9:267–276. [PubMed]
27. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. Proc Natl Acad Sci U S A. 1998;95:2509–2514. [PubMed]
28. Hua X, Liu X, Ansari DO, Lodish HF. Genes Dev. 1998;12:3084–3095. [PubMed]
29. Halbert CL, Demers GW, Galloway DA. J Virol. 1991;65:473–478. [PMC free article] [PubMed]
30. Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D’Andrea AD, Hua X. Cancer Res. 2003;63:4204–4210. [PubMed]
31. La P, Morgan T, Sykes S, Mao H, Schnepp R, Petersen C, Hua X. Oncogene. 2003;22:198–210. [PubMed]
32. Salmena L, Lemmers B, Hakem A, Matysiak-Zablocki E, Murakami K, Au PY, Berry DM, Tamblyn L, Shehabeldin A, Migon E, Wakeham A, Bouchard D, Yeh WC, McGlade JC, Ohashi PS, Hakem R. Genes Dev. 2003;17:883–895. [PubMed]
33. Hua X, Nohturfft A, Goldstein JL, Brown MS. Cell. 1996;87:415–426. [PubMed]
34. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES. Science. 1999;286:531–537. [PubMed]
35. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP. Cytometry. 1998;31:1–9. [PubMed]
36. Duke RC, Cohen JJ. Lymphokine Res. 1986;5:289–299. [PubMed]
37. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB. Genes Dev. 2001;15:1481–1486. [PubMed]
38. Chen G, Goeddel DV. Science. 2002;296:1634–1635. [PubMed]
39. Poisson A, Zablewska B, Gaudray P. Cancer Letters. 2003;189:1–10. [PubMed]
40. Chandrasekharappa SC, Teh BT. J Intern Med. 2003;253:606–615. [PubMed]
41. Hanahan D, Weinberg RA. Cell. 2000;100:57–70. [PubMed]
42. Saito Y, Swanson X, Mhashilkar AM, Oida Y, Schrock R, Branch CD, Chada S, Zumstein L, Ramesh R. Gene Ther. 2003;10:1961–1969. [PubMed]
43. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Cell. 1998;95:29–39. [PubMed]
44. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Cell. 1998;95:29–39. [PubMed]
45. Teitz T, Lahti JM, Kidd VJ. J Mol Med. 2001;79:428–436. [PubMed]
46. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM, Kidd VJ. Nat Med. 2000;6:529–535. [PubMed]
47. Ikeo Y, Sakurai A, Suzuki R, Zhang MX, Koizumi S, Takeuchi Y, Yumita W, Nakayama J, Hashizume K. Lab Invest. 2000;80:797–804. [PubMed]
48. Namihira H, Sato M, Murao K, Cao WM, Matsubara S, Imachi H, Niimi M, Dobashi H, Wong NC, Ishida T. J Mol Endocrinol. 2002;29:297–304. [PubMed]
49. Itakura Y, Sakurai A, Katai M, Ikeo Y, Hashizume K. Biomed Pharmacother. 2000;54(Suppl 1):187s–190s. [PubMed]
50. Scappaticci S, Brandi ML, Capra E, Cortinovis M, Maraschio P, Fraccaro M. Cancer Genet Cytogenet. 1992;63:17–21. [PubMed]
51. Scappaticci S, Maraschio P, del Ciotto N, Fossati GS, Zonta A, Fraccaro M. Cancer Genet Cytogenet. 1991;52:85–92. [PubMed]
52. Sherr CJ, DePinho RA. Cell. 2000;102:407–410. [PubMed]
53. Todaro G, Green H. J Cell Biol. 1963;17:299–313. [PMC free article] [PubMed]